Leukemia drug dasatinib promising for skin, breast, and other cancers
The leukemia drug dasatinib shows promise as a treatment for skin, breast, and several other cancers, according to new research.
Diagnosis & Disease Information
Dasatinib thwarts brain cancer metastasis after bevacizumab use
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Investigational drug is active against the most resistant types of chronic myeloid leukemia
A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.
Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer
A phase I trial determined that dasatinib 150 mg daily is the optimum dose when dasatinib is combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.
- Loading...
Loading...
Loading... 
Loading...